KR
Therapeutic Areas
Senti Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SENTI-202 | Acute Myeloid Leukemia (AML) | Phase 1 |
| Undisclosed Cell Therapy Programs | Challenging liquid and solid tumors | Preclinical |
Leadership Team at Senti Biosciences
TL
Timothy Lu
Co-Founder and Chief Executive Officer
JC
James Collins
Scientific Co-Founder
JC
Jay Cross
Chief Financial Officer
BC
Brenda Cooperstone
Board Member, Chief Development Officer, Pfizer Rare Disease
EM
Ed Mathers
Board Member, Partner, NEA